All articles tagged with #essential medicines
The WHO has added new drugs for obesity and diabetes, including GLP-1 medications like Ozempic and Mounjaro, to its essential medicines list, emphasizing the need for affordable generics in developing countries and highlighting their proven clinical benefits and potential for global health impact.
The WHO has updated its Essential Medicines Lists to include new treatments for cancer, diabetes, and other conditions, aiming to improve global access to vital medicines and address pressing health challenges like cancer and obesity.
A heart drug that combines three medications in one pill, known as a polypill, has been added to the World Health Organization's List of Essential Medicines. The polypill is designed to prevent repeat heart attacks and has been found to be effective in reducing cardiovascular mortality by 33% among patients who have previously had a heart attack. The pill contains acetylsalicylic acid, ramipril, and atorvastatin, which help thin the blood, lower blood pressure, and reduce cholesterol, respectively. The polypill improves medication adherence and is commercially available in 25 countries, but it has not yet been cleared for use in the United States.
A heart drug that combines three medications in one pill, known as a polypill, has been added to the World Health Organization's List of Essential Medicines. The polypill is designed for patients who have previously had a heart attack or other heart-related event, with the goal of preventing a repeat occurrence. It contains three medications commonly used to treat patients after a heart attack: acetylsalicylic acid, ramipril, and atorvastatin. The polypill has been found to be effective in preventing secondary adverse cardiovascular events and reducing cardiovascular mortality. It is commercially available in 25 countries but has not yet been cleared by the FDA for use in the United States.
The World Health Organization (WHO) has released updated editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), which now include new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions. The updated lists aim to improve access to innovative medicines that have clear clinical benefits, without straining the budgets of low- and middle-income countries. The additions to the lists include medications for multiple sclerosis, fixed-dose combinations for cardiovascular diseases, new treatments for infectious diseases, and additional cancer treatments. The WHO Model Lists serve as a global policy tool for selecting and providing affordable access to essential medicines.